AI-ACCELERATED DRUG DISCOVERY
Available from Reaxense
This protein is integrated into the Receptor.AI ecosystem as a prospective target with high therapeutic potential. We performed a comprehensive characterization of Guanine nucleotide-binding protein G(olf) subunit alpha including:
1. LLM-powered literature research
Our custom-tailored LLM extracted and formalized all relevant information about the protein from a large set of structured and unstructured data sources and stored it in the form of a Knowledge Graph. This comprehensive analysis allowed us to gain insight into Guanine nucleotide-binding protein G(olf) subunit alpha therapeutic significance, existing small molecule ligands, relevant off-targets, and protein-protein interactions.
Fig. 1. Preliminary target research workflow
2. AI-Driven Conformational Ensemble Generation
Starting from the initial protein structure, we employed advanced AI algorithms to predict alternative functional states of Guanine nucleotide-binding protein G(olf) subunit alpha, including large-scale conformational changes along "soft" collective coordinates. Through molecular simulations with AI-enhanced sampling and trajectory clustering, we explored the broad conformational space of the protein and identified its representative structures. Utilizing diffusion-based AI models and active learning AutoML, we generated a statistically robust ensemble of equilibrium protein conformations that capture the receptor's full dynamic behavior, providing a robust foundation for accurate structure-based drug design.
Fig. 2. AI-powered molecular dynamics simulations workflow
3. Binding pockets identification and characterization
We employed the AI-based pocket prediction module to discover orthosteric, allosteric, hidden, and cryptic binding pockets on the protein’s surface. Our technique integrates the LLM-driven literature search and structure-aware ensemble-based pocket detection algorithm that utilizes previously established protein dynamics. Tentative pockets are then subject to AI scoring and ranking with simultaneous detection of false positives. In the final step, the AI model assesses the druggability of each pocket enabling a comprehensive selection of the most promising pockets for further targeting.
Fig. 3. AI-based binding pocket detection workflow
4. AI-Powered Virtual Screening
Our ecosystem is equipped to perform AI-driven virtual screening on Guanine nucleotide-binding protein G(olf) subunit alpha. With access to a vast chemical space and cutting-edge AI docking algorithms, we can rapidly and reliably predict the most promising, novel, diverse, potent, and safe small molecule ligands of Guanine nucleotide-binding protein G(olf) subunit alpha. This approach allows us to achieve an excellent hit rate and to identify compounds ready for advanced lead discovery and optimization.
Fig. 4. The screening workflow of Receptor.AI
Receptor.AI, in partnership with Reaxense, developed a next-generation technology for on-demand focused library design to enable extensive target exploration.
The focused library for Guanine nucleotide-binding protein G(olf) subunit alpha includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Guanine nucleotide-binding protein G(olf) subunit alpha
partner:
Reaxense
upacc:
P38405
UPID:
GNAL_HUMAN
Alternative names:
Adenylate cyclase-stimulating G alpha protein, olfactory type
Alternative UPACC:
P38405; B7ZA26; Q86XU3
Background:
The Guanine nucleotide-binding protein G(olf) subunit alpha, also known as Adenylate cyclase-stimulating G alpha protein, olfactory type, plays a pivotal role in signal transduction within the olfactory neuroepithelium and the basal ganglia. It is instrumental in modulating various transmembrane signaling systems, potentially including aspects of visual transduction and hormone/neurotransmitter effects.
Therapeutic significance:
Dystonia 25, a disorder characterized by sustained involuntary muscle contraction and abnormal postures, is linked to variants affecting this protein's gene. Understanding the role of Guanine nucleotide-binding protein G(olf) subunit alpha could open doors to potential therapeutic strategies for treating this form of dystonia.
